To assess improvement of mild-to-moderate atopic dermatitis (AD) disease severity and pruritus with the use of crisaborole ointment 2%.

In the study, the researchers included pediatric patients aged ≥2 years with mild-to-moderate AD from 2 phase 3 studies. The severity of AD was determined by Investigator’s Static Global Assessment (ISGA) score.

Patients were randomly assigned 2:1 to receive either crisaborole or vehicle twice daily applied to affected areas (excluding the scalp) for 28 days in 2 identically designed, multicenter, double-blinded, vehicle-controlled phase 3 study. The ISGA outcomes included the number of patients and time to reaching an ISGA score of clear (0) or almost clear (1) with ≥2-grade improvement from the baseline. Moreover, on study days 8, 15, 22, and 29, investigators evaluated the share of patients achieving ISGA clear or almost clear and/or ≥1-grade improvement in ISGA. The Severity of Pruritus Scale (SPS) outcomes included the number of patients...

You do not currently have access to this content.